Sanofi and Translate Bio have started a phase-I clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza, the companies said on Tuesday.
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
Flu seasons dominated by A/H3N2 strain circulation activity tend to be more severe, especially among those considered at risk, such as older adults and younger children, the companies added.
Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…
https://youtu.be/mdl3AFFFcuk?si=i2cYzTX7WJ-z6wRp Does Chyawanprash Help in Cough & Cold? Exploring Its Benefits and Efficacy Chyawanprash, a…
Walk In Winter: In winter, the time from 7:00 AM to 9:00 AM is considered…
Does Maida Stick To Your Gut Lining: In this article, we debunk the common myth…
https://youtu.be/4NTKSfNf1TM?si=Y4xkEOKDUvqpIEZt The Disadvantages of Heating Packaged Milk Milk is a staple in many households and…
A recent study has revealed a growing mental health crisis among teenagers globally, with nearly…